VLCPUFA Composition for Retinal Membrane Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions such as age-related macular degeneration, atherosclerosis, fatty liver, obesity, and impaired cognitive function have limitations, and there is a need for more effective methods and compositions to address these health issues.
Innovation Solution
Administration of therapeutically effective amounts of very long chain polyunsaturated fatty acids (VLCPUFAs) with 24 to 40 carbon atoms, specifically C24:5 n-3, C26:6 n-3, or C28:8 n-3, to treat or ameliorate these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EPA+DHA supplementation is used to treat AMD, then heart benefits are achieved, but retinal function improvement is not observed
Solution Approach 1:
The patent changes the carbon chain length parameter of PUFA from conventional C20-C22 (EPA/DHA) to very long chain C24-C40 VLCPUFA. This parameter change enables the fatty acids to span both leaflets of the lipid bilayer, providing structural stability to highly curved cellular membranes in the retina and macula, thereby achieving therapeutic efficacy for AMD that EPA/DHA cannot provide.
Solution Approach 2:
The patent employs a composite approach by combining multiple VLCPUFA components (C24:5 n-3, C26:6 n-3, C28:8 n-3, and other C24-C40 PUFAs) in specific ratios within an oil composition. This composite formulation synergistically provides both retinal therapeutic benefits and cardiovascular protection, resolving the limitation of single-component EPA/DHA supplementation.
2Stability of the object's composition
If conventional PUFA (C16-C22) are used, then general health benefits are achieved, but stability of highly curved cellular membranes is not provided
Solution Approach 1:
The patent increases the carbon chain length parameter from conventional C16-C22 to very long chain C24-C40. This extension in chain length enables the VLCPUFA molecules to span the entire thickness of the lipid bilayer including both leaflets, providing structural stability to highly curved cellular membranes such as those surrounding nuclear pore complexes and photoreceptor outer segments.
3Reliability
If VLCPUFA are administered, then retinal and cognitive functions are improved, but lipid metabolism changes occur
Solution Approach 1:
The patent utilizes the specific parameter of very long carbon chain length (C24-C40) to achieve selective tissue distribution. The unique structure of VLCPUFA enables them to be incorporated into highly curved membrane structures in the retina and brain with high affinity, while their extended chain length prevents random incorporation into general adipose tissue, thereby minimizing unwanted lipid metabolism disruption and maximizing therapeutic efficacy in target organs.
Data Source
AI summary
The present invention is directed to methods for treating macular degeneration, atherosclerosis, fatty liver, obesity, and cognitive ability, and more specifically to methods for treating macular degeneration, atherosclerosis, fatty liver, obesity, and cognitive ability using very long chain polyunsaturated fatty acids having 24 to 40 carbon atoms.